Failure to Launch
Open Access
- 28 August 2017
- journal article
- review article
- Published by Elsevier BV in JACC: Basic To Translational Science
- Vol. 2 (4), 484-497
- https://doi.org/10.1016/j.jacbts.2017.07.001
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2013
- Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) TrialCardiovascular Drugs and Therapy, 2011
- Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean MalesPLOS ONE, 2011
- Soluble P-Selectin Levels Are Associated with Cardiovascular Mortality and Sudden Cardiac Death in Male Dialysis PatientsAmerican Journal of Nephrology, 2011
- Economic burden of illness of acute coronary syndromes: medical and productivity costsBMC Health Services Research, 2011
- Minor surgery in general practice and effects on referrals to hospital care: Observational studyBMC Health Services Research, 2011
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Concerning the mechanism of pexelizumab's benefit in acute myocardial infarctionAmerican Heart Journal, 2006
- Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesionsKidney International, 1999